首页 » 文章 » 文章详细信息
Cardiovascular Diabetology Volume 21 ,Issue 1 ,2022-10-21
One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis
Research
Hong Wang 1 Xiaoya Xie 2 Quannan Zu 3 Ming Lu 3 Rongfa Chen 4 Zhiren Yang 4 Yongqiang Gao 1
Show affiliations
DOI:10.1186/s12933-022-01673-8
Received 2022-4-18, accepted for publication 2022-10-21, Published 2022-10-21
PDF
摘要

BackgroundDiabetes mellitus (DM) and cardiovascular diseases often co-exist. Today, percutaneous coronary intervention (PCI) is the preferred revascularization procedure for majority of patients with coronary artery disease. Polymer-free amphilimus-eluting stents (AES) represent a novel elution technology in the current era of drug-eluting stents. In this analysis, we aimed to systematically compare the cardiovascular outcomes which are associated with polymer-free amphilimus-eluting stents (AES) versus the durable polymer zotarolimus-eluting stents (ZES) for the treatment of patients with DM.MethodsHttp://www.ClinicalTrials.gov, EMBASE, Web of Science, MEDLINE, Cochrane database and Google Scholar were searched for publications comparing polymer-free AES versus durable polymer ZES in patients with DM. Selective cardiovascular outcomes were assessed. Statistical analysis was carried out by the latest version of the RevMan software. Risk ratio (RR) with 95% confidence interval (CI) was used to represent the data analysis.ResultsFour studies with a total number of 1795 participants with DM whereby 912 patients were assigned to be revascularized by the polymer-free AES and 883 patients were assigned to be revascularized by the durable polymer ZES were included in this analysis. In patients with DM, at one year, polymer-free AES were associated with significantly lower risk of major adverse cardiac events (MACEs) (RR: 0.69, 95% CI: 0.54–0.88; P = 0.002) and target lesion failure (TLF) (RR: 0.66, 95% CI: 0.48–0.91; P = 0.01) compared to durable polymer ZES. However, there was no significant change in all-cause mortality (RR: 0.79, 95% CI: 0.51–1.22; P = 0.28), cardiac death and the other cardiovascular outcomes. Similar risk of total stent thrombosis (RR: 1.13, 95% CI: 0.60–2.13; P = 0.70), including definite stent thrombosis (RR: 1.12, 95% CI: 0.38–3.31; P = 0.84), probable stent thrombosis (RR: 0.87, 95% CI: 0.37–2.09; P = 0.76), possible stent thrombosis (RR: 1.19, 95% CI: 0.50–2.87; P = 0.69) and late stent thrombosis (RR: 1.00, 95% CI: 0.17–5.72; P = 1.00) as between polymer-free AES and durable polymer ZES in patients with DM.ConclusionsAt 1 year follow-up, polymer-free AES were associated with significantly lower MACEs and TLF compared to durable polymer ZES in these patients with DM, without any increase in mortality, stent thrombosis and other cardiovascular outcomes. However, this analysis is only based on a follow-up time period of one year, therefore, future research should focus on the long term follow-up time period.

关键词

Stent thrombosis;Major adverse cardiac events;Target lesion failure;Cardiovascular outcomes;Percutaneous coronary intervention;Durable polymer zotarolimus-eluting stents;Polymer-free Amphilimus-eluting stents;Diabetes mellitus

授权许可

© The Author(s) 2022
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

图表
通讯作者

Hong Wang.Department of Cardiology, The People’s Hospital of Guangxi Zhuang Autonomous Region, 530021, Nanning, Guangxi, People’s Republic of China.iriswh2014@163.com

推荐引用方式

Hong Wang,Xiaoya Xie,Quannan Zu,Ming Lu,Rongfa Chen,Zhiren Yang,Yongqiang Gao. One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis. Cardiovascular Diabetology ,Vol.21, Issue 1(2022)

您觉得这篇文章对您有帮助吗?
分享和收藏
0

是否收藏?

参考文献
[1] G Rodriguez-Araujo, H NakagamiPathophysiology of cardiovascular disease in diabetes mellitusCardiovasc Endocrinol Metab.201871491:CAS:528:DC
[2] 2BC1cXht12qs7vF10.1097/XCE.0000000000000141316462716739883
[3] C Bavishi, U Baber, S Panwar, S Pirrotta et al.Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: a meta-analysis of randomized trialsInt J Cardiol.201723031031810.1016/j.ijcard.2016.12.11628062139
[4] D CarriéAdvances with polymer-free amphilimus-eluting stentsMinerva Cardioangiol.20166433395326934663
[5] A Liberati, DG Altman, J Tetzlaff et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaborationBMJ.2009339b270010.1136/bmj.b2700196225522714672
[6] ND van Hemert, M Voskuil, R Rozemeijer et al.3-Year clinical outcomes after implantation of permanent-polymer versus polymer-free stent: ReCre8 landmark analysisJACC Cardiovasc Interv.202114222477248610.1016/j.jcin.2021.08.07834794654
[7] R Rozemeijer, IG van Muiden, S Koudstaal et al.One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: a propensity-score adjusted analysisCatheter Cardiovasc Interv.2019941616910.1002/ccd.28041306044936619187
[8] ND van Hemert, R Rozemeijer, M Voskuil et al.Clinical outcomes after permanent polymer or polymer-free stent implantation in patients with diabetes mellitus: the ReCre8 diabetes substudyCatheter Cardiovasc Interv.202299236637210.1002/ccd.2968533811730
[9] R Romaguera, JA Gómez-Hospital, J Gomez-Lara et al.A randomized comparison of reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus: the RESERVOIR clinical trialJACC Cardiovasc Interv.201691425010.1016/j.jcin.2015.09.02026762910
[10] R Romaguera, P Salinas, J Gomez-Lara et al.Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trialEur Heart J.20224313132013301:CAS:528:DC
[11] 2BB38Xis1elsLzK10.1093/eurheartj/ehab79034735004
[12] PK Bundhun, N Li, M ChenAdverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysisCardiovasc Diabetol.20151413510.1186/s12933-015-0300-6264468294597459
[13] EH Ploumen, TH Pinxterhuis, P Zocca et al.Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trialsCardiovasc Diabetol.20212012171:CAS:528:DC
[14] 2BB38Xktlyjs7w
[15] 3D10.1186/s12933-021-01405-4347176278557556
[16] R Rozemeijer, D Benedetto, AO Kraaijeveld et al.Clinical outcomes of complex real-world diaetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: a single-center registryCardiovasc Revasc Med.2018195 Pt A52152510.1016/j.carrev.2017.10.01129137966
[17] JPT Higgins, DG Altman, PC Gøtzsche et al.The Cochrane collaboration's tool for assessing risk of bias in randomised trialsBMJ.2011343d592810.1136/bmj.d5928220082173196245
[18] R Piccolo, GG Stefanini, A Franzone et al.Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysisCirc Cardiovasc Interv.201584e0022231:CAS:528:DC
[19] 2BC2MXntlWhtrk
[20] 3D10.1161/CIRCINTERVENTIONS.114.00222325858975
[21] A StangCritical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEur J Epidemiol201025960360510.1007/s10654-010-9491-z20652370
[22] Y Zhu, K Liu, M Chen et al.Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stentsCardiovasc Diabetol.20212011371:CAS:528:DC
[23] 2BB3MXitVSksLbK10.1186/s12933-021-01332-4342382948268452
[24] J Maeremans, D Cottens, L Azzalini et al.Outcomes of the amphilimus-eluting polymer-free stent for chronic total occlusion treatment: a multicentre experienceJ Cardiovasc Med (Hagerstown).201819105645701:CAS:528:DC
[25] 2BC1cXhsF2mt7zJ10.2459/JCM.0000000000000704
[26] K Ogurtsova, JDR Fernandes, Y Huang et al.Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040Diabetes Res Clin Pract.201712840501:STN:280:DC
[27] 2BC1crgs1Cisw
[28] 3D
[29] 3D10.1016/j.diabres.2017.03.02428437734
[30] Y Yang, J Hyun, J Lee et al.Effectiveness and safety of contemporary drug-eluting stents in patients with diabetes mellitusJACC Asia2021117318410.1016/j.jacasi.2021.07.009
[31] DW Park, JM Ahn, SJ Park, DP Taggart et al.Percutaneous coronary intervention in left main disease: SYNTAX, PRECOMBAT, EXCEL and NOBLE-combined cardiology and cardiac surgery perspectiveAnn Cardiothorac Surg.20187452152610.21037/acs.2018.04.04300942176082784
[32] Y Yoshikawa, H Shiomi, T Morimoto et al.Stent-related adverse events as related to dual antiplatelet therapy in first- vs second-generation drug-eluting stentsJACC Asia.2021134535610.1016/j.jacasi.2021.08.010
[33] RJ HenningType-2 diabetes mellitus and cardiovascular diseaseFuture Cardiol.20181464915091:CAS:528:DC
[34] 2BC1cXisV2lsrvK10.2217/fca-2018-004530409037
[35] KE Ashley, WB HillegassInsulin-treated diabetes mellitus: an actionable risk factor and marker after percutaneous coronary interventionCatheter Cardiovasc Interv.202096230931010.1002/ccd.2917032797736
文献评价指标
浏览 77次
下载全文 5次
评分次数 0次
用户评分 0.0分
分享 0次
相关文章